P1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE

• A. Reiter,
• J. Gotlib,
• I. Álvarez-Twose,
• D. H. Radia,
• J. Luebke,
• P. J. Bobbili,
• A. Wang,
• C. Norregaard,
• S. Dimitrijević,
• E. Sullivan,
• M. Louie-Gao,
• J. Schwaab,
• I. A. Galinsky,
• C. Perkins,
• W. R. Sperr,
• P. Sriskandarajah,
• A. Chin,
• S. R. Sendhil,
• M. S. Duh,
• P. Valent,
• D. J. DeAngelo

Affiliations

A. Reiter

1 Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany

J. Gotlib

2 Stanford Cancer Institute/Stanford University School of Medicine, Stanford, United States of America

I. Álvarez-Twose

3 Institute of Mastocytosis Studies of Castilla La Mancha (CLMast) ─ Spanish Reference Center (CSUR) for Mastocytosis and CIBERONC, Virgen del Valle Hospital, Toledo, Spain

D. H. Radia

4 Guy’s & St Thomas’ NHS Foundation Trust, Guy’s Hospital, London, United Kingdom

J. Luebke

1 Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany

P. J. Bobbili

5 Analysis Group, Inc., Boston

A. Wang

5 Analysis Group, Inc., Boston

C. Norregaard

6 Blueprint Medicines Corporation, Cambridge, United States of America

S. Dimitrijević

7 Blueprint Medicines Corporation, Zug, Switzerland

E. Sullivan

6 Blueprint Medicines Corporation, Cambridge, United States of America

M. Louie-Gao

6 Blueprint Medicines Corporation, Cambridge, United States of America

J. Schwaab

1 Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany

I. A. Galinsky

8 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America

C. Perkins

2 Stanford Cancer Institute/Stanford University School of Medicine, Stanford, United States of America

W. R. Sperr

9 Department of Internal Medicine I, Division of Hematology and Hemostaseology, and Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria

P. Sriskandarajah

4 Guy’s & St Thomas’ NHS Foundation Trust, Guy’s Hospital, London, United Kingdom

A. Chin

5 Analysis Group, Inc., Boston

S. R. Sendhil

5 Analysis Group, Inc., Boston

M. S. Duh

5 Analysis Group, Inc., Boston

P. Valent

9 Department of Internal Medicine I, Division of Hematology and Hemostaseology, and Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria

D. J. DeAngelo

8 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America